Germany is the bigger Asthma & COPD Drugs market: $1.8 Bn against $1.3 Bn in 2023, about 1.4 times as large.
Germany grows faster: 2.2% a year, against 2%.
Clinical research: 111 active trials in the UK, 61 in Germany.
| Measure |  UK |  Germany |
|---|---|---|
| Market size, 2023 | $1.3 Bn | $1.8 Bn |
| Market size, 2033 projected | $1.6 Bn | $2.3 Bn |
| Growth a year (CAGR) | 2% | 2.2% |
| Money added, 2023–2033 | $282 Mn | $440 Mn |
| Share of the world market | 2.6% | 3.7% |
| Size rank of 24 countries | #7 | #5 |
| Market per person, 2023 | $19 | $22 |
| Active clinical trials | 111 | 61 |
| Full report | UK report | Germany report |
Year by year, 2023 to 2033
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
UK Germany · values between 2023 and 2033 are projected from the 2023 size and the CAGR.
Quick answers
Which is bigger in Asthma & COPD Drugs, UK or Germany?
Germany is the bigger Asthma & COPD Drugs market: $1.8 Bn against $1.3 Bn in 2023, about 1.4 times as large.
Which grows faster in Asthma & COPD Drugs, UK or Germany?
Germany grows faster: 2.2% a year, against 2%.
More Asthma & COPD Drugs comparisons
Sources: market size and growth: Acuitas Health Analytics research (2023 base year, forecasts to 2033). Trials: ClinicalTrials.gov (fetched 10 Nov 2026); found by search words, so counts are a guide. Population: World Bank.